**Plasma Exosomes of Patients with Breast and Ovarian Tumors Contain an Inactive 20S Proteasome**

Natalia Yunusova, Elena Kolegova, Elena Sereda, Larisa Kolomiets, Alisa Villert, Marina Patysheva, Irina Rekeda, Alina Grigor’eva, Natalia Tarabanovskaya, Irina Kondakova and Svetlana Tamkovich

Abstract: Exosomes are directly involved in governing of physiological and pathological conditions of an organism through the transfer of information from producing to receiving cells. It can be assumed that exosomes are one of the key players of tumor dissemination since they are very stable and small enough to penetrate from various tissues into biological fluids and then back, thus interacting with tissue target cells. We evaluated the enzymatic activity and the level of 20S proteasome in tissue and exosomes of healthy females and patients with ovarian and breast tumors to reveal the critical role of exosomal cargo in the mediation of different types of metastases. Exosomes from plasma and ascites were isolated and characterized in accordance with International Society for Extracellular Vesicles guidelines. The level of 20S proteasome in tissue and exosomes was determined using Western blot analysis. Chymotrypsin- and caspase-like (ChTL and CL, respectively) peptidase activities of the proteasomes were determined using fluorogenic Suc-LLVY-AMC and Cbz-LLG-AMC substrates, respectively. We observed increased levels of 20S proteasome in ovarian cancer tissue and luminal B subtype breast cancer tissue as well as in plasma exosomes from cancer patients. Moreover, the level of the 20S proteasome in plasma exosomes and ascites exosomes in patients with ovarian tumors is comparable and higher in ovarian cancer patients with low volume ascites than in patients with moderate and high-volume ascites. We also found increased ChTL and CL activities in breast cancer and ovarian cancer tissues, as well as in peritoneal metastases in ovarian cancer, while proteasomal activity in exosomes from plasma of healthy females and all patients, as well as from ascites of ovarian tumor patients were lower than detection limit of assay. Thus, regardless of the type of tumor metastasis (lymphogenous or peritoneal), the exosomes of cancer patients were characterized by an increased level of 20S proteasome, which do not exhibit enzymatic activity.

Keywords: exosomes; 20S proteasome; plasma; tissue; breast cancer; ovarian cancer
1. Introduction

The study of the mechanisms of the metastases generation at the molecular level is necessary for the development of diagnostic approaches for predicting the risk of metastasis, prevention, and treatment of metastatic disease. Currently, it has been proven that one of the leading roles in metastasis belongs to proteases. These enzymes degrade the extracellular matrix, disrupt adhesive contacts, and induce angiogenesis [1]. It is known that the ubiquitin–proteasome system is the most important system of specific intracellular proteolysis, providing degradation of proteins in a wide range of cellular pathways [2].

In tissues, proteolysis occurs directly in the 20S proteasome, the core of which consists of four folded heptamer rings, including two outer α-rings and two inner β-rings. Activation of the 20S proteasome occurs through the attachment of regulatory particles to external α-subunits (19S, PA28). The two outer rings are composed of homologous α-subunits (α1α2α3α4α5α6α7). The N-terminal domains of the α-subunits form a kind of gate (pore) that opens or closes the access for the substrate to enter the catalytic cavity; α-subunits are also responsible for substrate recognition. Three of the seven β-subunits are catalytically active and provide proteolytic activity of the proteasome: β1-subunit has caspase-like activity (CL), β2-subunit has trypsin-like activity (TL), and β5-subunit demonstrates chymotrypsin-like activity (ChTL) [3,4]. Dysfunction of this complex can lead to regulatory proteins be stabilized due to reduced degradation or lost due to accelerated degradation [5]. Previous research has shown that tissue proteasome activity is associated with cancer progression and can be used to stratify risk [6,7].

Enzymatically active extracellular proteasomes have also been revealed in human plasma and cerebrospinal fluid [8–10]. Proteomic analysis of affinity-purified extracellular proteasomes revealed that extracellular proteasomes do not contain 19S or PA200 regulatory particles and are represented exclusively by the 20S complex [11]. Moreover, using matrix-assisted laser desorption/ionization Fourier transform ion cyclotron resonance mass spectrometry, were identified extracellular core 20S proteasome subunits and a set of 15 proteasome-interacting proteins, all previously described as exosome cargo proteins [11]. Taking this into account, as well as the fact that the 20S proteasome is a tetraspanin-unassociated protease of exosomes, it can be assumed that the most likely source of extracellular proteasomes are extracellular vesicles [11,12].

It is known that exosomes (endosome-derived vesicles (30–120 nm) [13]) are involved in such key physiological processes as intercellular communication [14], proliferation [15], migration [16,17], invasion [18], and angiogenesis [16,19] through horizontal transfer of RNA and proteins. On the one hand, exosomes are mini replicas of parent cells; on the other hand, selective transport of biologically active molecules has been shown in these vesicles [20]. It can be assumed that exosomes are one of the key players of tumor dissemination since they are very stable and small enough to penetrate from various tissues into biological fluids and then back, thus interacting with tissue target cells.

In our work we supposed critical role of exosomal 20S proteasome in mediating different types of metastasis. To test our hypothesis, we selected two female cancers (breast cancer and ovarian cancer) with different types of metastases (lymphogenic and peritoneal, correspondingly) and compared the enzymatic activity and the level of 20S proteasome in tissue and exosomes of healthy females and patients with ovarian and breast tumors.

2. Results

2.1. Characterization of Exosomes

The morphology of exosomes from blood plasma and ascites was examined by transmission electron microscopy. Presence of clearly structured cup-shaped particles of low electron density with a preserved membrane was revealed in exosome preparations isolated from blood plasma and ascites of breast cancer patients (BCPs), benign breast tumor patients (BBTPs), ovarian cancer patients (OCPs), benign ovarian tumor patients (BOTPs), and healthy females (HFs).
Vesicles with damaged membranes did not exceed 12%, and the portion of microvesicles (with the size smaller than 30 nm), was no more than 16% (Figure 1).

Nanoparticle tracking analysis (NTA) showed that EVs from HF plasma had a mean size of 88 nm, with a mode of 55 nm and an SD of 45 nm (Figure 2A). Similarly, EVs from BBTP plasma had a mean size of 95 nm, with a mode of 53 nm and an SD of 59 nm (Figure 2B). EVs from cancer patients plasma were slightly larger than in normal plasma: mean size of 123 and 118 nm, with a mode of 87 and 96 nm and an SD of 64 and 53 nm for BCP plasma and OCP plasma, correspondingly (Figure 2C,D). The size distribution of EVs from ascites (a mean size of 135 nm, with a mode of 90 nm and an SD of 80 nm) and from plasma of patients with ovarian cancer are similar (Figure 2E); however, in ascites of BOTPs the size distribution of EVs (a mean size of 132 nm, with a mode of 76 nm and an SD of 67 nm) is similar to the superposition of EVs from BOTP plasma (a mean size of 110 nm, with a mode of 71 nm and an SD of 83 nm) and EVs from OCP ascites (Figure 2F,G). According to the most rigorous definition, exosomes are extracellular membrane particles of endocytic origin ranging from 30 to 130 nm emerging during the formation of multivesicular bodies and secreted into the extracellular space as a result of the fusion of multivesicular bodies with the plasma membrane. Microvesicles are a number of extracellular membrane particles that, in addition to exosomes, include apoptotic blebs—membrane particles with a diameter of 50 to 500 nm separated from the cells in the process of apoptosis, and shedding microvesicles—microparticles with a diameter of 100 to 1000 nm secreted by various cells under physiological conditions and probably playing an important role, along with exosomes, in the cell-to-cell communication and transport of proteins and nucleic acids [21]. To confirm the exosomal nature of isolated exosome-like vesicles, EVs were inspected for the presence of exosomal markers (CD9, CD24, CD63, and CD81) using flow cytometry. For this, vesicles absorbed into aldehyde sulfate latex beads using anti-CD9 antibodies were stained with FITC-labeled antibodies to tetraspanin family receptors CD63 and CD81, as well as to CD24 receptor. A subpopulation of CD9/CD24-positive exosome-like vesicles predominated in all samples (Figure 2).
Collectively, obtained data reveal that the extracellular vesicles isolated from blood plasma and ascites have all properties of exosomes [22].
2.2. Proteasomal Activity and the Level of 20S Proteasome in Tissues

In the study, the significant increase in chymotrypsin-like proteasomal activity (ChTL) and caspase-like (CL) proteasomal activity in malignant breast and ovarian tumors, was identified in comparison to the normal tissues (Table 1).

Table 1. Proteasomal activity and the level of 20S proteasome in breast and ovarian cancer tissues.

| Biological Sample | Enzymatic Activity, $10^3$ U/mg Protein | Level of the 20S Proteasome ($\alpha + \beta$), RU |
|-------------------|--------------------------------------|-----------------------------------------------|
| Cancer tissues, $n = 80$ | 45.6 [19.8; 92.3] * | 0.72 [0.3; 2.5] |
| Adjacent tissues, $n = 80$ | 19.8 [10.3; 42.1] | 1.0 [0.3; 3.1] |
| Ovarian tissues, $n = 80$ | 30.0 [26.0; 45.2] ** | 0.9 [0.7; 2.5] |
| Normal tissues, $n = 10$ | 13.0 [7.8; 15.6] | 1.0 [0.5; 2.0] |

Note: Median and range value [25;75%], RU–related units. * Significant differences with adjacent breast tissue, $p < 0.05$; ** Significant differences with normal ovarian tissue, $p < 0.05$.

In particular, in breast cancer tissue the median values of ChTL and CL proteasomal activities were 2.3 and 3.0 times higher than in adjacent unchanged tissue. For ovarian cancer tissue the median values of these enzyme activities were 2.3 and 2.7 times higher than in normal ovary tissue too. It should be noted that the level of 20S proteasome was significantly increased in ovarian cancer tissue (at 1.7 times) and was comparable in breast cancer and adjacent unchanged breast tissue (Table 1, Figure 3A).

![Figure 3](image)

Figure 3. The 20S proteasome level in tissues, detected by Western blot. Western blotting was performed using antibodies against $\alpha$&$\beta$ subunits of 20S proteasome. $\beta$-Actin was used as the internal control. (A) Primary cancer tissues, adjacent breast tissue and normal ovarian and peritoneal metastasis tissues; (B) Luminal B subtype breast cancer tissue without ($N_0$) and with regional lymph node metastasis ($N_1$).

In total group of BCPs, there was no correlation of ChTL and CL activity of proteasome and the level of 20S proteasome in tumor tissue with age, molecular subtype, lymphovascular invasion and lymphogenous metastasis. Nevertheless, the level of 20S proteasome in tumor tissue was significantly higher (at 2.4 times) in patients with luminal B (HR + /HER2−) subtype with the presence of metastases in regional lymph nodes in comparison to patients without metastases (Table 2, Figure 3B).
Table 2. Relationship of the proteasomal activity and level of 20S proteasome in luminal B-like (HR + /Her2−) breast cancer and ovarian cancer tissues with lymphogenic and peritoneal metastasis.

| Biological Samples                                      | Enzymatic Activity, $10^3$ U/mg Protein | Level of the 20S Proteasome ($\alpha + \beta$), RU |
|---------------------------------------------------------|----------------------------------------|--------------------------------------------------|
| Cancer tissues, T$_1$N$_0$M$_0$, n = 25                 | 45.7 [28.7; 116.67]                    | 0.51 [0.3; 0.6]                                    |
| Cancer tissues, T$_1$N$_1$M$_0$, n = 24                 | 42.4 [18.52; 111.9]                    | 1.2 [0.9; 2.6] *                                  |
| Ovarian tissue                                          |                                        |                                                  |
| Cancer tissues, n = 30                                  | 30.0 [26.0; 45.2]                      | 1.7 [0.5; 2.9]                                    |
| Peritoneal metastases, n = 20                           | 60.5 [49.6; 66.6] **                   | 79.7 [44.6; 120.5] **                             |
| Note: Median and range value [25; 75%], RU–related units. * Significant differences between breast cancer tissue without and with metastases, $p < 0.05$; ** Significant differences between primary ovarian tumor and peritoneal metastasis, $p < 0.05$. |

At the same time, in patients with advanced ovarian cancer, the ChTL and CL activities of proteasome in the tissue of peritoneal metastases were significantly increased in comparison with the primary tumor (at 2.0 and 1.4 times, correspondingly) (Table 2, Figure 3A).

2.3. Proteasomal Activity and the Level 20S Proteasome in Exosomes from Plasma and Ascites of Tumor Patients

The ChTL proteasomal activity and CL proteasomal activity in exosomes from plasma of HFs and all patients, as well as from ascites of BOTPs and OCPs were lower than detection limit of assay (data not shown).

The 20S proteasome levels were significantly higher in BCP and OCP plasma exosomes (at 1.6 and 2.4 times, correspondingly) and did not differ in BBTP and BOTP plasma exosomes from plasma HF exosomes (Table 3, Figure 4A).

Table 3. The level of exosomal 20S proteasome and concentration of plasma exosomes from healthy female and tumor patients.

| Individuals | Level of the 20S Proteasome ($\alpha + \beta$), RU | Median and Range of Exosomes Concentration $\times 10^7$/mL |
|-------------|-------------------------------------------------|----------------------------------------------------------|
| HFs, n = 39 | 1.00 [0.90; 1.12] | 16 [8; 20] |
| BBTPs, n = 26 | 1.05 [0.95; 1.16] | 24 [20; 138] |
| BCPs, n = 80 | 1.59 [1.22; 1.61] * | 21 [10; 180] |
| BOTPs, n = 18 | 1.07 [0.85; 1.22] | 29 [17; 99] |
| OCPs, n = 30 | 2.42 [1.60; 4.58] * | 22 [13; 154] |

Note: Median and range value [25; 75%], RU–related units; * Significant differences between HFs and cancer patients, $p < 0.05$. 
NTA analysis revealed an increased concentration of exosomes in the blood plasma of tumor patients in comparison with HFs. Moreover, the concentration of exosomes in the cancer patient plasma was lower than in patients with benign tumors (Table 3). However, these differences were not significant.

It was shown that the level of 20S proteasome in the blood exosomes of tumor patients is associated with molecular subtype of breast cancer. In particular, the level of exosomal 20S proteasome was significantly higher in the triple-negative subtype than in the less aggressive luminal B subtypes (HER2-positive and HER2-negative) (Table 4, Figure 4B). However, the relationship of 20S proteasome level in BCP plasma exosomes with age, lymphovascular invasion, and lymphogenous metastasis was not revealed.

Table 4. The level of 20S proteasome in plasma exosomes from HFs and BCPs.

| Individuals          | Level of the 20S Proteasome (α + β), RU |
|----------------------|----------------------------------------|
| HFs, n = 39          | 1.00 [0.90; 1.12]                      |
| Luminal B HER2-positive, n = 49  | 1.56 [1.22; 1.59] *                  |
| Luminal B HER2-negative, n = 12   | 1.59 [1.52; 1.73] *                  |
| TN, n = 19           | 1.94 [1.58; 2.67] **                   |

Note: Median and range value [25; 75%], RU–related units; * Significant differences between HFs and BCPs, p < 0.05. ** Significant differences between Luminal B and TN breast cancer subtypes, p < 0.05.

The level of 20S proteasome was then investigated in plasma and in ascitic fluid in relation with ascites volume. The obtained data on the level of the exosomal proteasome from OCP plasma and from OCP ascites were compared with the corresponding samples from BOTPs. The level of ascites 20S proteasome was significantly higher in OCPs with low-volume ascites compared with the level observed in OCPs with moderate- and high-volume ascites (p = 0.048, Kruskal–Wallis test, Table 5, Figure 4C). A similar relationship was observed for blood plasma exosomes in OCPs, but the differences were not significant (p = 0.128, Kruskal–Wallis test, Table 5, Figure 4D). The relationship of 20S proteasome level in OCP plasma and ascites exosomes with age and stage of disease was not revealed.
Table 5. The level of 20S proteasome in exosomes from plasma and ascites of ovarian tumor patients.

| Patients | Ascites Volume | Level of the 20S Proteasome (α + β), RU |
|----------|----------------|----------------------------------------|
|          |                | Plasma | Ascites |
| OCPs, n = 30 | <200 mL, n = 8 | 2.80 [2.38; 4.30] * | 2.9 [2.39; 3.87] * |
|          | 200–1000 mL, n = 8 | 2.10 [1.07; 3.90] | 1.10 [0.77; 2.50] |
|          | >1000 mL, n = 14 | 2.00 [0.56; 3.36] | 1.50 [0.88; 2.70] |
| BOTPs, n = 20 |                | 1.00 [0.87; 1.20] | 1.00 [0.75; 1.44] |

Note: Median and range value [25, 75%], RU-related units; * Significant differences between BOTPs and OCPs, p < 0.05.

Regression analysis was performed to assess the relationship between the proteasomal activity and level of the 20S proteasome in breast and ovarian cancer with the most important clinical and morphological parameters. Significant relationships were revealed between the 20S proteasome level in BCP plasma exosomes with molecular subtype of breast cancer (Table 6).

Table 6. The proteasomal activity and the level of 20S proteasome in breast cancer and ovarian cancer: predicting tumor aggressiveness using regression analysis.

| B | Standard Error | p | 95.0% Confidence Interval |
|---|----------------|---|--------------------------|
| Breast Cancer Tissues (All Subtypes) | | | |
| Lymphovascular invasion | | | |
| ChTL | 0.003 | 0.009 | 0.777 | 0.985 | 1.021 |
| CL | 0.010 | 0.010 | 0.319 | 0.991 | 1.029 |
| 20S proteasome level | −0.032 | 0.016 | 0.546 | 0.938 | 1.099 |
| Multicentric type of tumor growth | | | |
| ChTL | −0.031 | 0.008 | 0.500 | 0.954 | 1.086 |
| CL | −0.033 | 0.012 | 0.785 | 0.946 | 1.090 |
| 20S proteasome level | −0.033 | 0.013 | 0.913 | 0.943 | 1.093 |
| Luminal B HER-2 negative subtype breast cancer tissues | | | |
| Lymphogenic metastasis | | | |
| ChTL | −0.005 | 0.244 | 0.983 | 0.616 | 1.606 |
| CL | 0.047 | 0.306 | 0.877 | 0.576 | 1.908 |
| 20S proteasome level | **0.011** | **0.015** | **0.049** | **0.932** | **0.999** |
| Plasma exosomes from BCPs | | | |
| Molecular subtype | | | |
| 20S proteasome level | **0.266** | **0.117** | **0.038** | **0.017** | **0.515** |
| Lymphovascular invasion | | | |
| 20S proteasome level | −0.664 | 0.341 | 0.071 | 0.264 | 1.004 |
| Plasma exosomes from OCPs | | | |
| Ascites volume | | | |
| 20S proteasome level | −0.006 | 0.017 | 0.058 | 0.133 | 0.656 |
| Ascites exosomes from OCPs | | | |
| Ascites volume | | | |
| 20S proteasome level | −0.066 | 0.135 | 0.056 | 0.764 | 0.995 |
The lack of reliable relationships between the 20S proteasome level in OCP plasma exosomes and in OCP ascites exosomes with volume of ascites, can be explained by the insufficient size of patient groups (Tables 5 and 6).

3. Discussion

Breast cancer and ovarian cancer occupy the leading places in the structure of cancer incidence in women, especially in industrialized countries [23]. In breast cancer, the definition of major molecular subtypes is often used in clinical practice to optimize the treatment of patients with both early and advanced cancer. Regardless of the molecular subtype of the tumor, the presence of lymphovascular invasion and lymphogenous metastases are prognostically unfavorable factors in breast cancer [24]. Ovarian cancer is characterized by high rates of one-year mortality, which indicates the aggressiveness of this tumor, which is mainly represented by G3 adenocarcinomas and is detected in 70% of cases at stage III [23]. Unlike lymphogenous metastatic neoplasms, tumor cells in ovarian cancer spread mainly inside the abdominal cavity. Malignant ascites constitute a tumor microenvironment that promotes migration and increased invasive activity of tumor cells due to the high content of cancerous exosomes and molecules with high biological activity (growth factors, cytokines, etc.). In OCPs, the presence of a large volume of ascites is associated with a low frequency of optimal cytoreduction and low overall survival [25].

Although malignant cells themselves are the major source of tumorigenesis, their interactions with the tumor microenvironment are critical for the progression from a single tumor mass to distant metastases [26]. It was shown that exosomes carry messages (proteins, non-coding RNA, DNA, lipids, metabolites) from transformed healthy cells or to other cells in the tumor or they may signal in an autocrine manner back to the producing tumor cells causing changes in the recipient cells behavior and microenvironment alterations [27–31]. Moreover, cargo of exosomes from tumor microenvironments such as ascites fluids has been found to be highly immunosuppressive [32–34], helping cancer progression and metastasis. Thus, it is probably the cargo of exosomes that is responsible for various types of metastasis (lymphogenous, peritoneal, etc.) of various malignant neoplasms.

We assessed the level of 20S proteasome and proteasomal activity both in tissues and in exosomes of healthy women and patients with female tumors to confirm for the first time the critical role of exosomal cargoes in mediating different types of metastases (lymphogenic and peritoneal). According to previous studies the significantly increased ChTL and CL proteasomal activities in ovarian cancer tissue were revealed in comparison to the normal tissues [7]. In addition, we revealed a significantly increased enzymatic proteasomal activity in the tissue of peritoneal metastases of OCPs. The level of 20S proteasome was significantly increased in cancer tissue and plasma exosomes from OCPs that reflect cell biology they stem from. These data are consistent with our previous study, which showed that 20S proteasome level was higher in samples of exosomes from SVO-3 culture medium than in exosomes from plasma OCPs and BOTPs as well as ascites of OCPs [35]. Moreover, it was found that the level of the 20S proteasome in plasma exosomes and ascites exosomes in patients with ovarian tumors is comparable, which can later be used to develop methods for evaluating the effectiveness of therapy and predicting the development of cancer. An unexpected artifact was the high level of 20S proteasome in the plasma exosomes and ascites exosomes from OCPs, which are characterized by a positive disease prognosis and a small volume of ascites. At the same time, these OCP exosomes have undetected enzymatic proteasomal activity, which may indirectly indicate the presence of proteasome inhibitors in their composition. Similar results were obtained for blood plasma exosomes from colorectal cancer patients: the level of 20S proteasomes in circulating exosomes was higher than in colorectal polyp patients, but the ChTL proteasomal activity was low or absent [36]. Moreover, in patients with Stage III colorectal cancer, the levels of 20S proteasomes (more than two units) and MMP9+ subpopulations (less than 60%) in plasma exosomes are favorable prognostic factors for overall survival. Another study found that despite comparable amounts of extracellular proteasomes from
concentrated conditioned medium and cellular proteasomes from whole-cell extract of K562 cells, the ChTL, CL, and TL peptidase activities of affinity purified extracellular proteasomes were about 50%, 25% and 15% of cellular proteasomes, respectively. Authors suggest that proteasome activity in the conditioned medium is inhibited by an unknown protein reversibly bound to extracellular proteasomes [11]. It is known that proteasome inhibitors have immunosuppressive effects [37,38]. Taking this into account, as well as the absence of proteasome enzymatic activity in the exosomes of plasma and ascites of OCPs, revealed in the current work, it can be assumed that it is proteasome inhibitors that cause the immunosuppressive effect of tumor exosomes.

In total breast cancer tissue, a significant increase of ChTL and CL proteasome activities was revealed, although the level of 20S proteasome in the primary tumor did not differ from the level in the adjacent tissue; only luminal B HER2-negative subtype BCPs with lymphogenic metastasis were characterized by significantly increased 20S proteasome level in the tissue. Despite the high level of 20S proteasome in blood plasma exosomes of BCPs, as in the case of exosomes of OCPs, the level of proteasome enzymatic activity was lower than the detection limit of the assay. At the same time, the level of 20S proteasome in exosomes of patients with triple-negative subtype was significantly higher than in exosomes of patients with luminal B subtype of breast cancer, which is estrogen-positive. The obtained results are consistent with our earlier data on a higher level of the 20S proteasome level in samples of exosomes from plasma malignant and non-malignant breast tumors as compared to those of MCF-7 culture medium [35]. It is known that the ubiquitin–proteasome system is an important mechanism for the down-regulation of ER [39] and allows the rapid removal of ER to maintain a proper cellular balance of ER protein levels in response to hormonal stimulation. Our obtained results allow suggesting that the exosomal cargos, rather than the amount of exosomes, play causal roles in the development of cancer therapy tolerance [40].

We assume that the increased content of the 20S proteasome, which does not exhibit enzymatic activity both in the exosomes of breast cancer patients and in the exosomes of ovarian cancer patients, revealed in this study, aids in the delivery of intact biologically active proteins (transcription factors, enzymes, etc.) from transformed cells to targets cells. Regardless of the type of metastasis (lymphogenic or peritoneal) in recipient cells, exosome-delivered proteasome-inhibitor complexes can dissociate and the enzymatically active proteasome can be involved in the regulation of multiple cellular processes through the elimination of proteins and/or generation peptides involved in these processes [41].

4. Materials and Methods
4.1. Human Samples

Blood samples from HF (n = 39, median age 40) were obtained from Novosibirsk Central Clinical Hospital. HF did not have any female disorders (dysplasia, endometriosis, etc.) or any malignant diseases. Blood samples from BBTP (n = 28, median age 42) and tissue and blood samples from BCP (n = 80, median age 56) were obtained from Novosibirsk Regional Oncology Dispensary and Tomsk National Research Medical Center (Table 7).

Tissue, blood, and ascites samples from BCP (n = 20, median age 38) and from OCP (n = 30, median age 56) were obtained from Tomsk National Research Medical Center (Table 8). Blood samples from all enrolled patients were collected before therapy. Tissue samples from BCPs were obtained as a result of the radical mastectomy or breast-conserving surgery, which was a first line of therapy. The volume of ovarian tumor patient’s ascites was measured clinically and by ultrasound examination. Three clinical subgroups of OCP were formed: patients having low-volume (<200 mL, n = 8), moderate-volume (200–1000 mL, n = 8) and high-volume ascites (>1000 mL, n = 14). All BCPs and OCPs underwent diagnostic laparoscopy for morphological verification and surgical staging as well as for sampling of tumor tissue and ascites.
Table 7. Clinical characteristics of BCPs.

|                      | Luminal B |                      | Triple Negative, n = 19 | Total Patients, n = 80 |
|----------------------|-----------|----------------------|-------------------------|------------------------|
|                      | HER-2 Negative, n = 49 | HER-2 Positive, n = 12 |                         |                        |
| Tumor stage          |           |                      |                         |                        |
| T1                   | 15 (31%)  | 4 (33%)              | 7 (37%)                 | 26 (33%)               |
| T2                   | 34 (69%)  | 8 (64%)              | 12 (63%)                | 54 (67%)               |
| Nodal status         |           |                      |                         |                        |
| N0                   | 25 (51%)  | 5 (42%)              | 13 (68%)                | 43 (54%)               |
| N1                   | 24 (49%)  | 7 (58%)              | 6 (32%)                 | 37 (46%)               |
| Tumor Grade          |           |                      |                         |                        |
| G2                   | 49 (100%) | 12 (100%)            | 19 (100%)               | 80 (100%)              |
| Lymphovascular invasion |           |                      |                         |                        |
| Positive             | 10 (20%)  | 2 (17%)              | 4 (21%)                 | 16 (20%)               |
| Negative             | 39 (80%)  | 10 (83%)             | 15 (79%)                | 64 (80%)               |
| Multicentric type of tumor growth |           |                      |                         |                        |
| Positive             | 8 (16%)   | 3 (25%)              | 0 (0%)                  | 11 (14%)               |
| Negative             | 41 (84%)  | 9 (75%)              | 19 (100%)               | 69 (86%)               |

Table 8. General clinical characteristics of the BOTPs and the OCPs.

|                      | BOTPs, n = 20 | OCPs, n = 30 |
|----------------------|---------------|--------------|
| Histology            |               |              |
| Serous               | 30 (100%)     |              |
| Other                | 20 (100%)     |              |
| FIGO (2013) staging  |               |              |
| I-II                 | 16 (80%)      |              |
| IIIB                 | 4 (20%)       | 5 (17%)      |
| IIC                  |               | 25 (83%)     |
| Tumor Grade          |               |              |
| High-grade           |               | 30 (100%)    |
| Not specify          | 20 (100%)     |              |
| BRCA status          |               |              |
| Negative             |               |              |
| Not specify          | 20 (100%)     | 30 (100%)    |
| Ascites volume       |               |              |
| <200 mL              | 8 (26.5%)     |              |
| 200–1000 mL          | 8 (27.5%)     |              |
| >1000 mL             | 14 (47%)      |              |
| Not specify          | 20 (100%)     |              |

Histological sections were prepared from paraffin blocks according to the standard method with the staining with hematoxylin-eosin. All ovarian cancers were characterized as high-grade serous adenocarcinomas.

4.2. Immunohistochemistry

Determination of the molecular subtype of breast cancer was carried out after assessing the receptor status in the operating material (expression of receptors for estrogen (ER) and progesterone (PR)), HER-2 status and the level of proliferative activity (expression of Ki67) in accordance with the St. Gallen Consensus Recommendation [42]. IHC was prepared as described [43]. For ER and PR expressions, the cases were classified as positive when nuclear immunoreactivity was in ≥1% of tumor cells according to the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines [44]. Sections stained with ER and PR were scored using the H-score method [45]. HER2 protein-positive status was defined as a score of 3+ by IHC or 2+ by IHC together with the confirmed c-erbB2 gene amplification by fluorescence in situ hybridization (FISH).
4.3. Clarified Tissue Homogenates

Tissue samples to determine the level of proteasome activity were collected at the stage of surgical intervention, frozen and stored at $-80^\circ$C. Breast and ovarian cancer tissues as well as samples of adjacent unchanged breast tissue of BCPs were used in the study. Tissue samples of a morphologically unchanged ovary were taken from healthy women operated for prophylactic purposes in the case of a BRCA mutation detection. Preparation of clarified homogenates was prepared as described [7].

4.4. Exosome Isolation

Venous blood (9 mL) was collected in K$_3$EDTA spray-coated vacutainers (Improvacuter, Guangzhou, Guangdong, China, cat. no. 694091210), immediately mixed using a rotary mixer, placed at $+4^\circ$C and processed within an hour after blood taking. To isolate plasma exosomes by ultrafiltration and differential ultracentrifugation, the previously described protocol was used [16]. The pellet containing plasma exosomes was re-suspended in 150 µL of PBS.

Ascites fluid (18 mL) was collected in same vacutainers during surgery of BOTPs and OCPs, immediately mixed using a rotary mixer, placed at $+4^\circ$C and processed within an hour after ascites taking. Ascites fluid was centrifuged at 1200×g for 20 min at 4°C, supernatant was transferred into a new tube, and centrifuged to pellet cell debris at 17,000×g at $4^\circ$C for 20 min. Ascites supernatants were diluted in PBS (P4417, Sigma, Saint Louis, MO, USA) in a 1:3 ratio, passed through a 100 nm pore-size filter (Minisart high flow, 16553-K, Sartorius, Göttingen, Germany), and the filtrates were centrifuged for 90 min at 100,000×g (4°C). Pellets were suspended in 12 mL PBS and again centrifuged for 90 min at 100,000×g (4°C). Then supernatants were removed, and the pellets were resuspended in 300 µL PBS.

Exosomes samples from plasma and ascites fluid were frozen in liquid nitrogen and stored in aliquots at $-80^\circ$C until required. The aliquots were thawed once before use.

4.5. Exosomes Characterization

Morphology of the isolated extracellular vesicles was assessed by transmission electron microscopy (TEM) as described previously [17]. The initial volumes of plasma or blood for the study of EV using the TEM were 20 mL.

The size and concentration of EVs were determined by NTA using the NanoSight NS300 (Malvern, UK) as described previously [16].

To evaluate the protein concentration of exosomes, a NanoOrange Protein Quantitation kit (NanoOrange® Protein Quantitation Kit, Molecular Probes, Eugene, OR, USA) was used in accordance with the manufacturer’s recommendations.

Quantitative analysis of the exosomal tetraspanines on the surface of the isolated extracellular vesicles was carried out using flow cytometry as described previously [46]. Flow cytometry was performed on the Cytoflex (Becman Coulter, BioBay, China), using CytExpert 2.0 Software. The MFI of stained exosomes was analyzed and compared to the isotype control (BD bioscience, Heidelberg, Germany).

4.6. Proteasome Activity Assay

ChTL and CL activities of the total pool of proteasomes (0.5–2 µL) were determined in clarified homogenates of tumor and untransformed tissues by the hydrolysis of a specific fluorogenic oligopeptide substrates Suc-LLVY-AMC [47] and Cbz-LLG-AMC, correspondingly [47,48]. Reaction mixture contained 20 mM Tris-HCl buffer (pH 7.5), 1 mM DTT, 5 mM MgCl$_2$, 1 mM ATP and 30 µM specific fluorogenic oligopeptide substrate. The reaction was performed at 37°C for 20 min and terminated with 1% SDS solution. A microplate reader with the excitation wavelength of 380 nm and the emission wavelength of 440 nm measured the fluorescence intensity. To evaluate the activity of admixture proteinases in samples, specific inhibitor of proteasomes, 5 µM MG132 (Sigma) was used in the same reaction mixture. The amount of enzyme that hydrolyzed 1 nmol specific fluorogenic
oligopeptide substrate within 1 min at 37 °C was considered one activity unit. Specific activity of proteasomes was expressed in activity units per 1 mg protein. Protein content was determined according to Lowry’s method.

ChTL and CL activities of the total pool of proteasomes were performed in the same way. Specific activity of proteasomes was expressed in activity units per 1 µg exosomal protein.

4.7. Western Blot Analysis

Aliquots of exosomes (30 µL, 7 µg of exosomal protein) were incubated for 90 min on ice with 7 µL of lysis buffer (125 mM Tris-HCl (pH 7.5), 750 mM NaCl, 0.5% SDS, 5% Triton X-100), and 3 µL of protease inhibitors cocktail (1 mM Aprotinin (Roche, Mannheim, Germany), 0.1 mM Pepstatin A (Tocris Bioscience, Bristol, UK), 0.1 mM Leupeptin (Roche, Mannheim, Germany)). Then, the samples were sonicated (Sonopuls mini20, MS1, ultrasonic sensor MS1, Bandelin, Berlin, Germany) during 1 min, then incubated with sample buffer at 95 °C for 7 min and centrifuged at 13,000 × g for 5 min. After centrifugation samples were applied to a 13% PAA gel for SDS-PAGE electrophoresis according to Lemmli. After electrophoresis, proteins were transferred to the PVDF membrane (Immobilon, Millipore, Singapore). The membrane was blocked with 1X iBind Solution (Life Technologies, Carlsbad, Germany) and incubated with primary antibody to 20S proteasomes (Anti-Proteasome 20S α + β subunit antibody (ab22673, Abcam, London, UK), dilution 1:2000) and anti-CD9 antibody (ab134375, Abcam, London, UK, dilution 1:2000) at 4 °C, then the membrane was washed and incubated with secondary antibody (goat anti-rabbit IgG-HRP (Santa Cruz Biotechnology, Dallas, TX, USA), 1:5000 dilution) in accordance with the instruction with automated Western blotting device iBind Western Device (Life Technologies, Tel-Aviv, Israel) for 3 h. Further the membrane was incubated with the Amersham ECL Western blotting detection analysis system (GE Healthcare, Little Chalfont, UK). The visualization was performed on the system ChemiDoc Touch (Bio-Rad, Singapore). The density of the bands was estimated using “ImageLab” computer program. The obtained results were standardized with regard to the level of CD9 in exosomes and the level of 20S proteasome from HF blood exosomes or BOTP ascites exosomes.

Western blotting of 20S proteasome in tissue supernatants was performed in the same way, except for the procedures of the supernatant incubation with lysis buffer and sonication. The obtained results were standardized with regard to the level of actin in tissue homogenates and the level of 20S proteasome from unchanged breast and normal ovarian tissues.

4.8. Statistical Analysis

The data were processed by SPSS Statistica 10.0 software and presented as median and interquartile range (Me [Q25; Q75]). To evaluate the difference, either Mann–Whitney or Kruskal–Wallis test was used. Linear regression analysis was performed to confirm the relationship between enzymatic activity and proteasome expression in tissues and in exosomes with the most important clinical and morphological parameters. p values < 0.05 were considered statistically significant.

Author Contributions: Conceptualization, N.Y., I.K. and S.T.; sample collection, L.K., I.R. and N.T.; investigation, N.Y., E.K., E.S., A.V., M.P., I.R., A.G. and S.T.; writing—original draft preparation, N.Y. and S.T.; writing—review and editing, S.T. All authors have read and agreed to the published version of the manuscript.

Funding: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for profit sectors.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Local Ethics Committee of the Cancer Research Institute of Tomsk National Research Medical Center (protocol N2 from 15 January 2020).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.
Data Availability Statement: Not Applicable.

Conflicts of Interest: The authors declare no conflict of interest.

Sample Availability: Samples of the compounds are not available from the authors.

References

1. Piperigkou, Z.; Kyriakopoulou, K.; Koutsakis, C.; Mastronikolis, S.; Karamanos, N.K. Key matrix remodeling enzymes: Functions and targeting in cancer. *Cancers 2021*, 13, 1441. [CrossRef] [PubMed]

2. Kim, S.H.; Baek, K.H. Regulation of cancer metabolism by deubiquitinating enzymes: The Warburg effect. *Int. J. Mol. Sci. 2021*, 22, 6173. [CrossRef] [PubMed]

3. Tanaka, K.; Mizushima, T.; Saeki, Y. The proteasome: Molecular machinery and pathophysiological roles. *Biol. Chem. 2012*, 393, 217–234. [CrossRef]

4. Jung, T.; Grune, T. Structure of the proteasome. *Prog. Mol. Biol. Transl. Sci. 2012*, 109, 1–39.

5. Zou, T.; Lin, Z. The involvement of ubiquitination machinery in cell cycle regulation and cancer progression. *Int. J. Mol. Sci. 2021*, 22, 5754. [CrossRef] [PubMed]

6. Wei, X.; Zeng, W.; Xie, K.; Diao, P.; Tang, P. Potential use of chymotrypsin-like proteasomal activity as a biomarker for prostate cancer. *Oncol. Lett. 2015*, 15, 5149–5154. [CrossRef]

7. Konochenko, M.; Sagaradze, G.; Orlova, E.; Shtam, T.; Proskura, K.; Kamyshinsky, R.; Yunusova, N.; Tamkovich, S. Total blood exosomes in breast cancer: Potential role in crucial steps of tumorigenesis. *Int. J. Mol. Sci. 2020*, 21, 7341. [CrossRef]

8. Sixt, S.U.; Dahlmann, B. Extracellular, circulating proteasomes and ubiquitin—incidence and relevance. *Biochim. Biophys. Acta 2008*, 1782, 817–823. [CrossRef]

9. Romaniuk, W.; Bolkun, L.; Kalita, J.; Galar, M.; Bernatowicz, M.; Ostrowska, H.; Kloczko, J. High chymotrypsin-like activity in the plasma of patients with newly diagnosed multiple myeloma treated with bortezomib is predictive of a better response and longer PFS. *Ann. Hematol. 2018*, 97, 1879–1887. [CrossRef] [PubMed]

10. Mueller, O.; Anlasik, T.; Wiedemann, J.; Thomassen, J.; Wohlschlaeger, J.; Hagel, V.; Keyvani, K.; Schwieger, I.; Dahlmann, B.; Sure, U.; et al. Circulating extracellular proteasome in the cerebrospinal fluid: A study on concentration and proteolytic activity. *J. Mol. Neurosci. 2012*, 46, 509–515. [CrossRef] [PubMed]

11. Kulichkova, V.A.; Artamonova, T.O.; Lyublinskaya, O.G.; Khodorkovskii, M.A.; Tomilin, A.N.; Tsimokha, A.S. Proteomic analysis of affinity-purified extracellular proteasomes reveals exclusively 20S complexes. *Onco Targets Ther. 2017*, 8, 102134–102149. [CrossRef]

12. Tsimokha, A.S.; Artamonova, T.O.; Diakonov, E.E.; Khodorkovskii, M.A.; Tomilin, A.N. Post-translational modifications of extracellular proteasome. *Molecules 2020*, 25, 3504. [CrossRef]

13. Osaki, M.; Okada, F. Exosomes and their role in cancer progression. *Yonago Acta Med. 2019*, 62, 182–190. [CrossRef] [PubMed]

14. Semina, S.E.; Cherbakov, A.M.; Vnukova, A.A.; Bagrov, D.V.; Evtushenko, E.G.; Safronova, V.M.; Golovina, D.A.; Lyubchenko, L.N.; Gudkova, M.V.; Krasil’nikov, M.A. Exosome-mediated transfer of cancer cell resistance to antiestrogen drugs. *Molecules 2018*, 23, 829. [CrossRef] [PubMed]

15. Li, Z.; Tao, Y.; Wang, X.; Jiang, P.; Li, J.; Peng, M.; Zhang, X.; Chen, K.; Liu, H.; Zhen, P.; et al. Tumor-secreted exosomal miR-222 promotes tumor progression via regulating p27 expression and re-localization in pancreatic cancer. *Cell. Physiol. Biochem. 2018*, 51, 610–629. [CrossRef] [PubMed]

16. Konoshenko, M.; Sagardaze, G.; Orlova, E.; Shtam, T.; Prosкуra, K.; Kamysẖinsky, R.; Yunusова, N.; Alexandrovа, A.; Efimenko, A.; Tamkovich, S. Total blood exosomes in breast cancer: Potential role in crucial steps of tumorigenesis. *Int. J. Mol. Sci. 2020*, 21, 7341. [CrossRef]

17. Tutanov, O.; Orlova, E.; Prosкура, K.; Griго’eva, A.; Yunусова, N.; Tsentalovich, Y.; Alexandrovа, A.; Tamkovich, S. Proteomic analysis of blood exosomes from healthy females and breast cancer patients reveals an association between different exosomal bioactivity on non-tumorigenic epithelial cell and breast cancer cell migration in vitro. *Biomolecules 2020*, 10, 495. [CrossRef] [PubMed]

18. Shtam, T.; Naryzhny, S.; Samsonov, R.; Karasik, D.; Mизgирев, I.; Petrenko, E.; Zabrodskaya, Y.; Kamysẖinsky, R.; Никитин, D.; et al. Plasma exosomes stimulate breast cancer metastasis through surface interactions and activation of FAK signaling. *Breast Cancer Res. Treat. 2019*, 174, 129–141. [CrossRef]

19. Li, Z.; Zeng, C.; Nong, Q.; Long, F.; Liu, J.; Mu, Z.; Chen, B.; Wu, D.; Wu, H. Exosomal leucine-rich-alpha2-glycoprotein 1 derived from non-small-cell lung cancer cells promotes angiogenesis via TGF-β signal pathway. *Mol. Ther. Oncolytics 2019*, 14, 313–322. [CrossRef] [PubMed]

20. Kossinova, O.A.; Gopanenko, A.V.; Tamkovich, S.N.; Krasheninina, O.A.; Tупикин, A.E.; Kiselevа, E.; Yanshina, D.D.; Malygin, A.A.; Ven’yaminova, A.G.; Kabilov, M.R.; et al. Cytosolic YB-1 and NSUN2 are the only proteins recognizing specific motifs present in mRNAs enriched in exosomes. *Biochim. Biophys. Acta Proteins Proteom. 2017*, 1865, 664–673. [CrossRef] [PubMed]

21. Tamkovich, S.N.; Tutanov, O.S.; Laktionov, P.P. Exosomes: Generation, structure, transport, biological activity, and diagnostic application. *Biochem. Suppl. Ser. A Membr. Cell Biol. 2016*, 10, 163–173. [CrossRef]
22. Théry, C.; Witwer, K.W.; Aikawa, E.; Alcaraz, M.J.; Anderson, J.D.; Andiriansitohaina, R.; Antoniou, A.; Arab, T.; Archer, F.; Atkin-Smith, G.K.; et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): A position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. *J. Extracell. Vesicles* 2018, 7, 1535750. [CrossRef]

23. Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J. Clin.* 2021, 71, 209–249. [CrossRef] [PubMed]

24. Burstein, H.J.; Curigliano, G.; Loibl, S.; Dubsky, P.; Gnant, M.; Poortmans, P.; Colleoni, M.; Carsten, D.; Piccart-Gebhart, M.; Regan, M.; et al. Estimating the benefits of therapy for early stage breast cancer the St Gallen international consensus guidelines for the primary therapy of early breast cancer 2019. *Ann. Oncol.* 2019, 30, 1541–1557. [CrossRef]

25. Morimoto, A.; Nagao, S.; Kogiku, A.; Yamamoto, K.; Miwa, M.; Wakahashi, S.; Ichida, K.; Sudo, T.; Yamaguchi, S.; Fujiwara, K. A preoperative low cancer antigen 125 level (≤ 25.8 mg/dl) is a useful criterion to determine the optimal timing of interval debulking surgery following neoadjuvant chemotherapy in epithelial ovarian cancer. *Ipn. J. Clin. Oncol.* 2016, 46, 517–521. [CrossRef]

26. Gerashchenko, T.S.; Novikov, N.M.; Krakhmal, N.V.; Zolotaryova, S.Y.; Zavyalova, M.V.; Cherdyntseva, N.V.; Denisov, E.V.; Perelmuter, V.M. Markers of cancer cell invasion: Are they good enough? *J. Clin. Med.* 2019, 8, 1092. [CrossRef]

27. Grigoryeva, E.S.; Savelieva, O.E.; Popova, N.O.; Cherdyntseva, N.V.; Perelmuter, V.M. Do tumor exosomes integrins alone determine organotropic metastasis? *Mol. Biol. Rep.* 2020, 47, 8145–8157. [CrossRef] [PubMed]

28. Croft, P.K.-d.; Sharma, S.; Godbole, N.; Rice, G.E.; Salomon, C. Ovarian-cancer-associated extracellular vesicles: Microenvironmental regulation and potential clinical applications. *Cancers* 2021, 10, 2272. [CrossRef]

29. Gao, L.; Nie, X.; Gou, R.; Hu, Y.; Dong, H.; Li, X.; Lin, B. Exosomal ANXA2 derived from ovarian cancer cells regulates epithelial-mesenchymal plasticity of human peritoneal mesothelial cells. *J. Cell. Mol. Med.* 2021. [CrossRef] [PubMed]

30. Ju, R.; Chen, X.; Zhang, S.; Liu, B.; Pei, H.; Tu, F.; Liu, J.; Yu, H. Plasma exosome-derived fragile-site associated tumor suppressor is a powerful predictor of prognosis in patients with ovarian cancer. *Bosni. J. Basic Med. Sci.* 2021, 7. [CrossRef]

31. Yang, L.; Wu, H.; Zhu, Y.; Chen, X.; Chen, Y. Plasma exosomal caveolin-1 predicts poor prognosis in ovarian cancer. *J. Cancer 2021*, 12, 5005–5012. [CrossRef]

32. Shenoy, G.N.; Loyall, J.; Maguire, O.; Iyer, V.; Kelleher, R.J., Jr.; Minderman, H.; Wallace, P.K.; Odunsi, K.; Balu-Iyer, S.V.; Bankert, R.B. Exosomes associated with human tumors harbor a reversible checkpoint of T-cell responses. *Cancer Immunol. Res.* 2018, 6, 236–247. [CrossRef]

33. Kelleher, R.J., Jr.; Balu-Iyer, S.; Loyall, J.; Sacca, A.J.; Shenoy, G.N.; Peng, P.; Iyer, V.; Fathallah, A.M.; Berenson, C.S.; Wallace, P.K.; et al. Extracellular vesicles present in human ovarian tumor microenvironments induce a phosphatidylserine-dependent arrest in the t-cell signaling cascade. *Cancer Immunol. Res.* 2015, 3, 1269–1278. [CrossRef] [PubMed]

34. Shenoy, G.N.; Loyall, J.; Berenson, C.S.; Kelleher, R.J., Jr.; Iyer, V.; Balu-Iyer, S.V.; Odunsi, K.; Bankert, R.B. Sialic acid-dependent inhibition of T cells by exosomal ganglioside GD3 in ovarian tumor microenvironments. *J. Immunol.* 2018, 201, 3750–3758. [CrossRef]

35. Tamkovich, S.N.; Yunusova, N.V.; Tugutova, E.; Somov, A.K.; Proskura, K.V.; Kolomiets, L.A.; Stakheeva, M.N.; Grigor’eva, A.E.; Laktionov, P.P.; Kondakova, I.V. Protease cargo in circulating exosomes of breast cancer and ovarian cancer patients. *Asian Pac. J. Cancer Prev.* 2019, 20, 255–262. [CrossRef]

36. Yunusova, N.V.; Zambalova, E.A.; Patysheva, M.R.; Kolegova, E.S.; Afanas’ev, S.G.; Cheremisina, O.V.; Grigor’eva, A.E.; Tamkovich, S.N.; Kondakova, I.V. Exosomal protease cargo as prognostic biomarker in colorectal cancer. *Asian Pac. J. Cancer Prev.* 2021, 22, 861–869. [CrossRef] [PubMed]

37. Berges, C.; Haberstock, H.; Fuchs, D.; Miltz, M.; Sadeghi, M.; Opelz, G.; Daniel, V.; Naujokat, C. Proteasome inhibition suppresses essential immune functions of human CD4+ T cells. *Immunology* 2008, 124, 234–246. [CrossRef] [PubMed]

38. Moran, E.; Carbone, F.; Augusti, V.; Patrone, F.; Ballestrero, A.; Nencioni, A. Proteasome inhibitors as immunosuppressants: Biological rationale and clinical experience. *Semin. Hematol.* 2012, 49, 270–276. [CrossRef]

39. Tecalco-Cruz, A.C.; Ramirez-Jarquin, J.O. Mechanisms that increase stability of estrogen receptor alpha in breast cancer. *Clin. Breast Cancer* 2017, 17, 1–10. [CrossRef] [PubMed]

40. Sannino, S.; Brodsky, J.L. Targeting protein quality control pathways in breast cancer. *BMC Biol.* 2017, 15, 109. [CrossRef]

41. Yerlikaya, A.; Kanbur, E.; Stanley, B.A.; Türner, E. The Ubiquitin-proteasome pathway and epigenetic modifications in cancer. *Anticancer Agents Med. Chem.* 2021, 21, 20–32. [CrossRef] [PubMed]

42. Curigliano, G.; Burstein, H.J.; Winer, E.P.; Gnant, M.; Dubsky, P.; Loibl, S.; Colleoni, M.; Regan, M.M.; Piccart-Gebhart, M.; Senn, H.J.; et al. De-escalating and escalating treatments for early-stage breast cancer: The St. Gallen international expert consensus conference on the primary therapy of early breast cancer 2017. *Ann. Oncol.* 2017, 28, 1700–1712. [CrossRef]

43. Babyshkina, N.; Votrushin, S.; Dronova, T.; Patalyak, S.; Slonimskaya, E.; Kzhyskhowska, J.; Cherdyntseva, N.; Choyzonov, E. Impact of estrogen receptor α on the tamoxifen response and prognosis in luminal-A-like and luminal-B-like breast cancer. *Clin. Exp. Med.* 2019, 19, 547–556. [CrossRef]

44. Hammonds, M.E.; Hayes, D.F.; Dowsett, M.; Allred, D.C.; Hagerty, K.L.; Badve, S.; Fitzgibbons, P.L.; Francis, G.; Goldstein, N.S.; Hayes, M.; et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). *Arch. Pathol. Lab. Med.* 2010, 134, e48–e72. [CrossRef]
45. Lessey, B.A.; Palomino, W.A.; Apparao, K.B.; Young, S.L.; Lininger, R.A. Estrogen receptor-alpha (ER-alpha) and defects in uterine receptivity in women. Reprod. Biol. Endocrinol. 2006, 4 (Suppl. 1), S9. [CrossRef] [PubMed]

46. Yunusova, N.V.; Patysheva, M.R.; Molchanov, S.V.; Zambalova, E.A.; Grigor’eva, A.E.; Kolomiets, L.A.; Ochirov, M.O.; Tamkovich, S.N.; Kondakova, I.V. Metalloproteinases at the surface of small extracellular vesicles in advanced ovarian cancer: Relationships with ascites volume and peritoneal canceromatosis index. Clin. Chim. Acta 2019, 494, 116–122. [CrossRef]

47. Ben-Shahar, S.; Komlosh, A.; Nadav, E.; Shaked, I.; Ziv, T.; Admon, A.; DeMartino, G.N.; Reiss, Y. 26S proteasome-mediated production of an authentic major histocompatibility class I-restricted epitope from an intact protein substrate. J. Biol. Chem. 1999, 274, 21963–21972. [CrossRef]

48. Ma, W.; Kantarjian, H.; Bekele, B.; Donahue, A.C.; Zhang, X.; Zhang, Z.J.; O’Brien, S.; Estey, E.; Estrov, Z.; Cortes, J.; et al. Proteasome enzymatic activities in plasma as risk stratification of patients with acute myeloid leukemia and advanced-stage myelodysplastic syndrome. Clin. Cancer Res. 2009, 15, 3820–3826. [CrossRef] [PubMed]